DEPOSITARY RECEIPTS

NEW DR ANNOUNCEMENT

Zealand Pharma A/S

Zealand Pharma is a biotechnology company. The Company is engaged in the discovery development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.

DR Name:	Zealand Pharma
Effective Date:	August 14, 2017
Country of Incorporation:	Denmark
Exchange:	NASDAQ Stock Market
Type of ADR Program:	Sponsored - Level III
Ticker Symbol:	ZEAL
CUSIP Number:	98920Y304
Ratio (DR:ORD):	1 : 1
Underlying Share Description:	Ordinary
Industry Classification:	Pharma. & Biotech.
Custodian(s) :	Danske Bank

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Ravi Davis / Rick Maehr
DR Broker Liaison
adrdesk@bnymellon.com
+1 212 815 2267

London

Jacek Jankowski
DR Broker Liaison
jacek.jankowski@bnymellon.com
+44 207 163 7427

DEPOSITARY RECEIPTS

BNY MELLON